Walvax Biotechnology announced that the adsorbed tetanus vaccine jointly applied for clinical trials by the company and its controlling subsidiary, Yuxi Walvax Biotechnology Co., Ltd., recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The notification number is: 2024LP02710, acceptance number: CXSL2400584, registration classification: biological products for prevention. According to related public information from the China Food and Drug Inspection Research Institute, from 2021 to the third quarter of 2024, the total number of batches of adsorbed tetanus vaccines authorized nationwide is 162 batches.